Please assess the completion status of the following clinical trial:

Trial Title: Exacerbation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults aged ≥40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure~* Patients diagnosed with COPD at age 40 and over and with a current diagnosis of severe COPD and including:~  1. Smoking history of at least 10 pack years, both current and ex-smokers are eligible~ 2. A documented history of at least 1 moderate or severe exacerbation in the previous 12 months~Exclusion Criteria:~* Patients who have received systemic corticosteroids and/or antibiotics for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol (Type: EXPERIMENTAL): Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 µg o.d. delivered via the handihaler®

Based on this trial design, predict the completion outcome and termination type (if applicable).